Clover Health Q2 2025 Earnings: Medicare Advantage Membership Grows 32%, Total Revenues Increase 34%

Clover Health Investments Corp reported Q2 2025 earnings with a 32% YoY increase in Medicare Advantage membership to 106,323 and a 34% rise in total revenues to $478 million. Despite a GAAP net loss of $11 million, the company achieved an adjusted EBITDA of $17 million and an adjusted net income of $17 million. The company maintained its full-year 2025 guidance and remains optimistic about sustaining growth and profitability.

Clover Health Investments Corp (CLOV) reported its second-quarter 2025 earnings, showcasing robust growth and profitability despite a challenging market environment. The company's Medicare Advantage membership surged by 32% year-over-year (YoY) to 106,323 members, while total revenues climbed by 34% to $478 million. Despite a GAAP net loss of $11 million, Clover Health achieved an adjusted EBITDA of $17 million and an adjusted net income of $17 million.

The company's strong performance was driven by significant increases in Medicare Advantage membership and insurance revenue. Membership grew to 106,323, a 32% rise from the previous year, while insurance revenue increased by 34% to $470 million. The company maintained an adjusted EBITDA of $70 million, indicating strong operational efficiency despite the challenging market conditions.

Clover Health's stock price initially dipped by 1.04% to $2.88 at market close but recovered slightly in after-hours trading, gaining 0.69% to $2.9. The stock's performance reflects mixed investor sentiment, possibly influenced by broader market trends and the company's increased insurance benefit ratio.

The company maintained its full-year 2025 guidance and remains optimistic about sustaining growth and profitability. Clover Health's CEO, Andrew Toy, emphasized the company's growth and profitability, stating, "We are growing significantly, operating profitably and differentiating ourselves through our technology-first model." The company anticipates financial benefits from a 4-star payment rating in 2026, which could enhance profitability and growth.

InvestingPro analysis indicates that Clover Health is currently undervalued, with a "GREAT" overall Financial Health score of 3.06 out of 5. Analyst consensus remains cautiously optimistic, with price targets ranging from $3.75 to $6.00 per share.

Key Takeaways:
- Medicare Advantage membership grew by 32% YoY to 106,323.
- Total revenues increased by 34% to $478 million.
- Adjusted EBITDA reached $70 million for the quarter.
- The stock price initially fell by 1.04% but recovered in after-hours trading.

References:
[1] https://za.investing.com/news/transcripts/earnings-call-transcript-clover-health-q2-2025-sees-revenue-beat-stock-dips-93CH-3821297